Ftse Mib
33.766,29
-0,06%
DAX
19.884,75
-0,57%
S&P 500
5.930,85
1,09%
NASDAQ
19.572,60
1,03%
Bitcoin
96.853,13
-0,36%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Aptose Biosciences Inc (APTO) Aptose Biosciences Inc (APTO) Notizie

Aptose Biosciences Inc

APTO
0,225
0,0548 (32,20%)
21 Dic 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
19/12/202422:10EDGAR2Form 8-K - Current report
19/12/202422:05GLOBEAptose Announces Positive Decision by Nasdaq Hearings Panel
13/12/202423:03EDGAR2Form PRE 14A - Other preliminary proxy statements
12/12/202416:30EDGAR2Form 8-K - Current report
12/12/202416:15GLOBEAptose Announces Publication of Preclinical Data in AACR..
09/12/202418:05EDGAR2Form 8-K - Current report
09/12/202418:00GLOBEAptose Clinical Data Featured in Poster Presentation at the..
03/12/202413:45EDGAR2Form 8-K - Current report
03/12/202413:30GLOBEAptose Signs CRADA with NCI to Develop Tuspetinib for AML..
27/11/202400:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/11/202422:27EDGAR2Form 8-K - Current report
25/11/202422:15GLOBEAptose Biosciences Inc. Announces Closing of $8 Million..
25/11/202412:05EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
22/11/202414:05EDGAR2Form 8-K - Current report
22/11/202414:00GLOBEAptose Biosciences Inc. Announces Pricing of $8 Million..
22/11/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
20/11/202414:00EDGAR2Form 8-K - Current report
20/11/202413:30GLOBEAptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed..
14/11/202421:22EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
08/11/202422:02EDGAR2Form 8-K - Current report
08/11/202422:01GLOBEAptose Reports Results for the Third Quarter 2024
31/10/202411:39EDGAR2Form S-1/A - General form for registration of securities..
04/10/202422:15EDGAR2Form 8-K - Current report
06/9/202422:15EDGAR2Form 8-K - Current report
05/9/202422:20EDGAR2Form 8-K - Current report
05/9/202422:15GLOBEAptose Announces Results from Special Meeting of..
30/8/202422:35EDGAR2Form 8-K - Current report
30/8/202422:30GLOBEAptose Receives $10 Million Through a Facility Agreement..
15/8/202422:35EDGAR2Form 8-K - Current report
15/8/202422:30GLOBEAptose Announces Adjournment of its Special Meeting of..
08/8/202423:22EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202423:15EDGAR2Form 8-K - Current report
08/8/202423:06GLOBEAptose Reports Results for the Second Quarter 2024
26/7/202422:30EDGAR2Form 8-K - Current report
19/7/202423:00EDGAR2Form 8-K - Current report
19/7/202423:00GLOBEAptose Announces Receipt of Deficiency Notice from Nasdaq
17/7/202417:43EDGAR2Form DEF 14A - Other definitive proxy statements
14/6/202413:40EDGAR2Form 8-K - Current report
03/6/202422:35EDGAR2Form 8-K - Current report
03/6/202416:32EDGAR2Form 8-K - Current report
03/6/202412:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
31/5/202414:05EDGAR2Form 8-K - Current report
15/5/202417:47EDGAR2Form DEF 14A - Other definitive proxy statements
14/5/202423:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/5/202422:15EDGAR2Form 8-K - Current report
10/5/202417:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/5/202422:45EDGAR2Form 8-K - Current report
01/3/202423:00EDGAR2Form 8-K - Current report
14/2/202422:51EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/2/202400:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 0,27 Min: 0,2106 Max: 0,3895
Chiusura: 0,1702

La tua Cronologia

NASDAQ
APTO
Aptose Biosciences
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network